You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Of the 29 companies in the index, 16 firms' share prices retreated while the other 13 saw their stock prices rise month over month.
The study will evaluate how Prolaris impacts prostate cancer treatment decisions, and how those decisions impact costs within UK's National Health Service.
Of the 27 companies in the index, 14 firms' stocks were down, while 13 companies' share prices increased.
A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractor Palmetto for the week of 8/22/2019.
The firm reported total revenues of $215.4 million, up from $193.9 million in fiscal Q4 2018, but below the consensus Wall Street estimate of $221.0 million.
The test will be used to identify which metastatic, castration-resistant prostate cancer patients harbor germline BRCA mutations and will likely benefit from Lynparza.
The firm said that UHC will cover the test for patients with major depressive disorder or anxiety who have failed to respond to one or more treatments.
The company decided to settle the complaint in order to avoid "lengthy and distracting litigation," but denies any wrongdoing.
Though the designation has seen slow uptake thus far, three tests received ADLT status in May, bringing the total number of approved ADLTs to five.
Five hundred pharmacies will provide information about pharmacogenetic testing to members who have failed one or more antidepressant treatments.